Ripe for the picking: Little biotech firms are catching the eye of Big Pharma. Juicy stocks?

Only a small number of biotechnology firms have clinical test results to show a prospective bidder and such validated products are commanding high prices in the new license deals and acquisitions. In picking possible beneficiaries, firms with new treatments for the toughest medical problems, like cancer are highlighted.